Hong Kong Pharma Digital Technology Holdings Limited operates at the forefront of biotechnology and digital healthcare, dedicated to enhancing patient outcomes through innovative pharmaceutical services. The company leverages advanced digital solutions and data analytics to optimize drug development and improve operational efficiencies, establishing itself as a vital participant in the rapidly evolving healthcare landscape. With a strong emphasis on health technology advancement and strategic partnerships, Hong Kong Pharma is strategically positioned to address both domestic and global market needs while driving innovation within its service portfolio.
| Revenue (TTM) | $16.36M |
| Gross Profit (TTM) | $1.44M |
| EBITDA | -534,478 |
| Operating Margin | 2.96% |
| Return on Equity | -13.40% |
| Return on Assets | -3.94% |
| Revenue/Share (TTM) | $1.53 |
| Book Value | $0.47 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 0.76 |
| EV/Revenue | 0.749 |
| EV/EBITDA | 28.39 |
| Quarterly Earnings Growth (YoY) | -83.10% |
| Quarterly Revenue Growth (YoY) | -35.70% |
| Shares Outstanding | $16.35M |
| Float | $7.36M |
| % Insiders | 62.26% |
| % Institutions | 0.32% |
Volatility is currently expanding